Therefore, BCR-ABL blocks TXNIP transactivation by disrupting a Miz-1-p300 complex via c-Myc induction, which was compromised in CML cells with imatinib treatment. The gene discussed is MYC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.